

Applications and Markets

“Personalised” medicine

Increasingly in the News is “Personalised” medicine or the ‘management of a patient’s disease or disposition by using molecular knowledge to achieve the best possible medicinal outcome.’ Too often this is narrowly defined as using the patient’s genetic information to achieve best drug therapy, so called pharmacogenomics.

Whilst the effects of drug treatment are known to vary greatly between different individuals, the use of pharmaco-genomics may be of limited practical help. More important will be the environmental factors (such as disease or condition, age, nutritional status, gut bacterial activities, and other drug use) for determining an individual’s metabolic makeup, which affects drug metabolism, efficacy, and toxicity.

Recent studies in the UK have demonstrated that pre-dose metabolite profiling can influence drug treatment outcomes.

Probe Scientific is working with leading researchers to highlight the benefits of continuous, automated real-time online monitoring (CAR-TOM) for metabolite profiling and drug and metabolite determination. The company sees opportunities in research, clinical drug studies, and Therapeutic Drug Monitoring (TDM).

